Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05684965 · ClinicalTrials.gov registry record · Phase 1
XTX301 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Xilio Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 358
- Enrollment target
- 11
- Study locations
NCT05684965: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Xilio Development.
NCT05684965 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Xilio Development. The registered enrollment target is 358 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (87% higher). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05684965, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Xilio Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 358 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG XTX301
Study Locations (11)
Ohio
- The Gabrail Pharmacology Phase 1 Research Center - Canton
- University Hospital Cleveland Medical Center - Cleveland
- The Ohio State University Wexner Medical Center - Columbus
California
- University of California, Davis Comprehensive Cancer Center - Sacramento
Connecticut
- Yale Cancer Center - New Haven
Minnesota
- HealthPartners Frauenshuh Cancer center - Saint Louis Park
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Hackensack University Medical Center - Hackensack
Pennsylvania
- University of Pittsburgh Medical Center-Hillman Cancer Center - Pittsburgh
Texas
- Tranquil Clinical Research - Webster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2023-05-11 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
What NCT05684965 shows while recruiting
NCT05684965 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (87% higher).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which XTX301 is the first listed.
NCT05684965 lists 11 locations in 9 states (Ohio, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05684965 about?
NCT05684965 is a clinical study titled "XTX301 in Patients With Advanced Solid Tumors". This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
What is the current status of trial NCT05684965?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 358 participants. The study started on 2023-05-11. Estimated completion is 2027-02.
What conditions does trial NCT05684965 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT05684965?
The interventions under investigation include: XTX301 (DRUG).
Who is sponsoring clinical trial NCT05684965?
This trial is sponsored by Xilio Development, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05684965 being conducted?
This trial has 11 study locations across California, Connecticut, Minnesota, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05684965's enrollment target sits among peer trials
358 22nd of 189 higher than 167 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373317 · 358 participants · Phase 4
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- NCT06480227 · 358 participants · NA
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
- NCT06859424 · 358 participants · Phase 2
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- NCT06914648 · 358 participants · NA
The Dragon PLC Trial (DRAGON-PLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI